Report overview
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is estimated to be $xx million in 2023, and it will reach $xx million by 2032, growing at a CAGR of xx% during the forecast period from 2024 to 2032.
This report studies the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, covering market size for segment by type (Eluxadoline, Rifaximin, etc.), by application (Rx, OTC, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Astellas Pharmaceuticals, Actavis, Pfizer, GlaxoSmithKline, Salix Pharmaceuticals, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical analysis of global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs from 2018-2023, and provides extensive market forecasts from 2024-2032 by region/country and subsectors. It covers the sales/revenue/value, gross margin, historical growth and future perspectives in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
Leading Players of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs including:
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals
AstraZenenca
Ironwood Pharmaceuticals
Allergan
Takeda Pharmaceutical
Sebela Pharmaceuticals
Synergy Pharmaceuticals
Synthetic Biologics
Bausch Health
Market split by Type:
Eluxadoline
Rifaximin
Alosetron
Loperamide
Diphenoxylate + Atropine
Market split by Application:
Rx
OTC
Market split by Sales Channel:
Direct Channel
Distribution Channel
Market split by Region/Country:
North America (United States and Canada)
Europe (Germany, UK, France, Italy, Spain, and Russia, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia, etc.)
South America (Brazil, Mexico, and Argentina, etc.)
Middle East & Africa (Turkey, UAE, Saudi Arabia, and South Africa, etc.)
If you have any special requirements, please let us know and we can provide you the customized report as you want.
